09 Feb 2022 --- In the latest move for medical nutrition, one of Lallemand Health Solutions’ probiotics is coming under the microscope for its potential to slow the progression of amyotrophic lateral sclerosis (ALS). This investigation of L. rhamnosus HA-114 will be one of the projects undertaken by Alex Parker and members of his laboratory at the Centre Hospitalier de l’Université de Montréal Research Center (CRCHUM), which has been awarded a CA$1.6 million (US$1.3 million) grant from the Weston Family Foundation.
